首页> 美国卫生研究院文献>other >Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroids: an updated decision analysis following the 2014 Food and Drug Administration safety communications
【2h】

Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroids: an updated decision analysis following the 2014 Food and Drug Administration safety communications

机译:腹腔镜子宫切除术与腹腔子宫切除术对子宫肌瘤的推测:根据2014年美国食品药品监督管理局安全通报的最新决策分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Previous decision analyses demonstrate the safety of minimally invasive hysterectomy for presumed benign fibroids, accounting for the risk of occult leiomyosarcoma and the differential mortality risk associated with laparotomy. Studies published since the 2014 Food and Drug Administration safety communications offer updated leiomyosarcoma incidence estimates. Incorporating these studies suggests that mortality rates are low following hysterectomy for presumed benign fibroids overall, and a minimally invasive approach remains a safe option. Risk associated with morcellation, however, increases in women age >50 years due to increased leiomyosarcoma rates, an important finding for patient-centered discussions of treatment options for fibroids.
机译:先前的决策分析表明,对于假定的良性肌瘤,微创子宫切除术是安全的,这说明了隐匿性平滑肌肉瘤的风险以及与剖腹手术相关的死亡率差异风险。自2014年美国食品药品监督管理局安全通讯以来发表的研究提供了更新的平滑肌肉瘤发病率估算值。纳入这些研究表明,子宫切除术后总体认为良性肌瘤的死亡率很低,并且微创方法仍然是安全的选择。然而,由于平滑肌肉瘤的发病率升高,年龄大于50岁的女性与粉碎相关的风险增加,这是以患者为中心的肌瘤治疗方案讨论的重要发现。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号